ZYVOX May Lead to Shorter Hospital Stays

Article

TORONTO - Data recently presented during the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, Canada show that ZYVOX (linezolid injection, tablets and for oral suspension) may help some patients with certain difficult-to-treat infections be discharged from hospitals sooner. ZYVOX, according to its manufacturer Pharmacia, is associated with a significantly higher rate of hospital discharge in the first week of therapy among patients with complicated skin and soft tissue infections. For more information visit www.pharmacia.com.

Recent Videos
Anthony Bondon CRCST, CHL, BSM, AAS, SME, LSSYB
Deannard Esnard, CRCST, CIS, CER, CHL, CFER, CQUIA
Kevin Bush, Jr, DHSc, EdD, MSHA, MA, MS, FACHE
Vatsala Rangachar Srinivasa, MPH
Sarah Vinson, MBA, CRCST
Kevin Anderson, MBA, BS, CRCST, Senior Manager, Commercial Education Services, Heatlthmark, a Getinge Company
Damien Berg, BA, BS, CRCST, AAMIF, is the vice president of strategic initiatives for the HSPA.
Annet Adegboyega, DNP, MSN, BSN, RN, CNOR; Mihyun "Rose" Jang, MSN, MPH, BSN, RN, CNOR; and Renilda Tijones, MSN, BSN, RN, CNOR.
Roundtable of Vet IPs (Adobe Stock)
APIC 2025 President Carol McLay, DrPH, MPH, RN, CIC FAPIC   (Image credit: APIC)
Related Content